Eriksen S, Keller L R
Graduate School of Management, University of California, Irvine.
Med Decis Making. 1993 Apr-Jun;13(2):118-25. doi: 10.1177/0272989X9301300205.
Both the selection of doses of pharmaceutical agents and comparisons between pharmaceutical agents have long been based on the nonquantified concept of the risk-benefit ratio. Though useful, this concept implies a data comparison that is difficult to make: the toxicity versus the efficacy of a drug compound. This research demonstrates an approach for weighing risks and benefits by combining utility functions for human efficacy and toxicity with animal and laboratory toxicity information to develop an overall multiattribute utility function for an ophthalmic pharmaceutical agent, I-bunolol, intended for the treatment of glaucoma. With this multiattribute function and a small portion of the published data available for this drug, the expected utilities for six doses (including a control) could be compared and the value of this approach in drug-dosage selection demonstrated.
药物制剂剂量的选择以及不同药物制剂之间的比较长期以来都基于风险效益比这一未量化的概念。尽管这个概念很有用，但它意味着一种难以进行的数据比较：药物化合物的毒性与疗效之间的比较。本研究展示了一种权衡风险和效益的方法，即将人类疗效和毒性的效用函数与动物及实验室毒性信息相结合，以开发一种用于治疗青光眼的眼科药物制剂——I - 布诺洛尔的整体多属性效用函数。利用这个多属性函数以及该药物已发表数据的一小部分，可以比较六种剂量（包括一个对照）的预期效用，并证明这种方法在药物剂量选择中的价值。
